Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

More documents

Recommendations

Info

Clinical Outcome in Coronary Drug Project** Event Rate (%) 35 30 25 20 15 10 5 0 -14%* Nonfatal MI/CD Death -27%* Nonfatal MI -26%* Stroke/ TIA Placebo Niacin -47%* CV Surgery JAMA 1975;231:360-381 *P
HATS: Angiographic and Clinical Endpoints Change in Stenosis, % 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 +3.9 * -0.4 Placebo Statin + Niacin *p
Page 1 and 2: Treating Lipid Abnormalities Beyond
Page 3 and 4: THE PYRAMID OF CVD TRIALS Very high
Page 5 and 6: UNMET CLINICAL NEED TREATMENT OF TH
Page 7 and 8: Lipoprotein Metabolism in Patients
Page 9 and 10: LOW HDL-C AS A RESIDUAL RISK FACTOR
Page 11 and 12: THE BEGINNING …
Page 13 and 14: THE RESULT… OF THE SUPER SIZED LI
Page 15 and 16: Current Insights into the Mechanism
Page 17 and 18: Lipid Poor ApoA-I and αHDL αHDL i
Page 19 and 20: Intestine ApoA-I Current Model of H
Page 21 and 22: COLLAR-INDUCED CHANGES IN ENDOTHELI
Page 27 and 28: Potential Mechanisms Involved in th
Page 29 and 30: Increasing HDL By Infusion of HDL,
Page 31: HDL Targeted Therapies: Niacin 1. D
Page 35 and 36: � � Aim High randomized 3414 pa
Page 37 and 38: Change in IVUS Total Atheroma Volum
Page 39 and 40: Future HDL Targeted Therapies 1. Pr
Page 41 and 42: Preβ-HDL Infusion Reduced Arterial
Page 43 and 44: Preβ-HDL Enriched Plasma Obtained
Page 45 and 46: The Reduction in Plaque was Greater
Page 47 and 48: Intestine ApoA-I Lipoprotein Profil
Page 49 and 50: 10 mg 30 mg 60 mg Plasma HDLC and L
Page 51 and 52: ILLUMINATE: Investigation of Lipid
Page 53 and 54: CETP Inhibitors CETP Torcetrapib Da
Page 55 and 56: The dal-HEART Program: Dalcetrapib
Page 57 and 58: LDL (mg/dL) Define Trial: Effect of
Page 59: FUTURE THERAPY FOR CARDIOVASCULAR D

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?